FierceBiotech7d
ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Business Insider5d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... E+P continues to ...
Zacks.com on MSN18h
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
New cancer jab that 'primes body to recognise and fight tumours'
The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...
Cancer breakthrough as new vaccine ‘stops tumours in their tracks and prevents new disease’
A GROUNDBREAKING cancer vaccine could stop tumours growing in patients with advanced disease, researchers say. Designed to ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to CF33-hNIS in Cholangiocarcinoma
CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...
GlobalData on MSN8d
ESMO: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
New cancer jab that trains body to 'recognise' tumours could treat advanced cases of disease
A pioneering vaccine designed to train the body to identify and fight cancer cells is showing early signs of success, ...